H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock
Published on 10/06/2026 at 12:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gyre Therapeutics (ISIN US4037831033) was trading at EUR 6.63 at Lang & Schwarz on October 6, 2026, at 12:22 p.m. CEST, up 1.22 percent versus the October 5 prior close of EUR 6.55. On October 5, 2026, H.C. Wainwright analyst Matthew Keller maintained a Buy rating and a USD 18.00 price target, according to Moomoo News.
Analyst target stays well above price
The USD 18.00 target is 157.14 percent above the Lang & Schwarz price when comparing the two currencies separately only as a cited analyst reference, not as a direct return calculation. The more useful signal is the unchanged Buy view from a named analyst while the stock remains below the companys recent US market range.
MarketBeat reported on October 3, 2026, that Wall Street Zen upgraded Gyre Therapeutics from Sell to Hold and that the broader analyst average was Reduce with a USD 16.00 target. That creates a clear split between the USD 18.00 H.C. Wainwright target and the USD 16.00 average cited by MarketBeat.
Second-quarter revenue beats estimates
Gyre Therapeutics generated USD 29.11 million of revenue in the second quarter of 2026, above the USD 26.49 million consensus estimate, according to MarketBeat. The company also reported a loss per share of USD 0.12 versus a USD 0.06 expected loss, making the revenue beat less decisive than the headline sales figure.
The companys investor-relations page lists the second-quarter 2026 results release dated August 7, 2026, alongside a September 3, 2026 conference update, according to Gyre Therapeutics. The next quarterly reporting date shown by a market-data page is November 6, 2026, which gives investors a defined point for the next operating update.
Stock remains below yearly high
On the Nasdaq, Gyre Therapeutics was last quoted at USD 7.35 on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 819.4 million. Its 52-week range was USD 5.44 to USD 9.42, leaving the Nasdaq quote 21.97 percent below the high and 35.11 percent above the low.
For Germany-based investors, the reference remains the EUR quote: Gyre Therapeutics was trading at EUR 6.63 at Lang & Schwarz on October 6, 2026 at 12:22 p.m. CEST, plus 1.22 percent versus the EUR 6.55 prior close. The contrast between the revenue beat, the loss per share and the differing analyst targets defines the next valuation debate.
Gyre Therapeutics market snapshot
- Company: Gyre Therapeutics, Inc.
- ISIN: US4037831033
- Ticker: GYRE
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 6, 2026, 12:22 p.m. CEST: EUR 6.63
- Change versus prior close: plus 1.22 percent
- Prior close Lang & Schwarz October 5, 2026: EUR 6.55
- Market capitalization: USD 819.4 million as of October 5, 2026
- 52-week range: USD 5.44-9.42 as of October 5, 2026
- Sector / Industry: Healthcare / Biotechnology
